These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

724 related items for PubMed ID: 19597025

  • 1. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H, German Chronic Lymphocytic Leukemia Study Group.
    J Clin Oncol; 2009 Aug 20; 27(24):3994-4001. PubMed ID: 19597025
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
    Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, Demirtas D, Grossschmidt P, Tatzreiter G, Gastl G, Greil R, Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia.
    Cancer; 2006 Nov 15; 107(10):2408-16. PubMed ID: 17054106
    [Abstract] [Full Text] [Related]

  • 4. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
    Cortelezzi A, Pasquini MC, Gardellini A, Gianelli U, Bossi A, Reda G, Sarina B, Musto P, Barcellini W, Neri A, Deliliers GL.
    Leukemia; 2009 Nov 15; 23(11):2027-33. PubMed ID: 19641526
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, Greco FA.
    Cancer; 2008 Mar 15; 112(6):1288-95. PubMed ID: 18189296
    [Abstract] [Full Text] [Related]

  • 6. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
    Molica S, Montillo M, Ribatti D, Mirabelli R, Tedeschi A, Ricci F, Veronese S, Vacca A, Morra E.
    Haematologica; 2007 Oct 15; 92(10):1367-74. PubMed ID: 17768114
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
    Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, Larson RA.
    Leuk Lymphoma; 2009 Oct 15; 50(10):1589-96. PubMed ID: 19863336
    [Abstract] [Full Text] [Related]

  • 9. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Ferrajoli A, Wierda WG, LaPushin R, O'Brien SM, Faderl S, Browning ML, Keating MJ.
    Eur J Haematol; 2008 Apr 15; 80(4):296-8. PubMed ID: 18182081
    [Abstract] [Full Text] [Related]

  • 10. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
    Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santábarbara P, Wacker B, Brettman L.
    J Clin Oncol; 2002 Sep 15; 20(18):3891-7. PubMed ID: 12228210
    [Abstract] [Full Text] [Related]

  • 11. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
    Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jäger G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Döhner H, Kneba M, Emmerich B, Hallek M, German CLL Study Group (GCLLSG).
    Leukemia; 2004 Jun 15; 18(6):1093-101. PubMed ID: 15071604
    [Abstract] [Full Text] [Related]

  • 12. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM.
    J Clin Oncol; 2011 Sep 10; 29(26):3559-66. PubMed ID: 21844497
    [Abstract] [Full Text] [Related]

  • 13. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
    Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J.
    J Clin Oncol; 2007 Dec 10; 25(35):5616-23. PubMed ID: 17984186
    [Abstract] [Full Text] [Related]

  • 14. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
    Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A.
    J Clin Oncol; 2005 Oct 01; 23(28):7024-31. PubMed ID: 16145065
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
    Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, Keegan P, Pazdur R.
    Clin Cancer Res; 2010 Sep 01; 16(17):4331-8. PubMed ID: 20601446
    [Abstract] [Full Text] [Related]

  • 17. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
    Lin TS, Flinn IW, Lucas MS, Porcu P, Sickler J, Moran ME, Lucas DM, Heerema NA, Grever MR, Byrd JC.
    Leukemia; 2005 Jul 01; 19(7):1207-10. PubMed ID: 15858611
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Robak T.
    Expert Rev Anticancer Ther; 2008 Jul 01; 8(7):1033-51. PubMed ID: 18588450
    [Abstract] [Full Text] [Related]

  • 20. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.
    Mauro FR, Molica S, Laurenti L, Cortelezzi A, Carella AM, Zaja F, Chiarenza A, Angrilli F, Nobile F, Marasca R, Musolino C, Brugiatelli M, Piciocchi A, Vignetti M, Fazi P, Gentile G, De Propris MS, Della Starza I, Marinelli M, Chiaretti S, Del Giudice I, Nanni M, Albano F, Cuneo A, Guarini A, Foà R, Gruppo Italiano Malattie EMatologiche dell’Adulto Working Party for Chronic Lymphoproliferative Disorders.
    Leuk Res; 2014 Feb 01; 38(2):198-203. PubMed ID: 24314589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.